Study guide

18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health

Key Takeaways Explain This Topic AI

A drug reaches steady state, and is mostly eliminated after stopping, in about 4–5 half-lives; potency (dose needed) and efficacy (maximum effect) are different properties.

CYP2D6 ultrarapid metabolizers convert codeine and tramadol to more active opioids, so the FDA warns against their use while breastfeeding and in children under 12.

Rifampin, rifabutin, and enzyme-inducing antiseizure drugs (carbamazepine, oxcarbazepine, phenytoin, phenobarbital, primidone, and topiramate above 200 mg/day) make combined pills and progestin-only pills US MEC Category 3; DMPA and IUDs are preferred.

Common non-rifamycin antibiotics do not reduce hormonal contraceptive effectiveness (US MEC Category 1).

Combined hormonal contraceptives lower lamotrigine levels by about half, risking seizures during active pills and toxicity in the hormone-free week.

Last updated: October 2026

Pharmacodynamics: What the Drug Does to the Body

Agonists activate receptors; partial agonists (buprenorphine) cap the maximum effect; antagonists block receptors (mifepristone at the progesterone receptor; naloxone at the opioid receptor).

Selective receptor modulators act as agonists in some tissues and antagonists in others:

Tamoxifen (a SERM): antagonist in breast, agonist in endometrium (polyps, hyperplasia, cancer) and bone.

Raloxifene: antagonist in breast and endometrium, agonist in bone.

Ulipristal (an SPRM): delays ovulation for emergency contraception.

GnRH agonists (leuprolide) cause an initial flare, then downregulate the pituitary; GnRH antagonists (elagolix, relugolix) suppress immediately without a flare.

Potency vs. efficacy: Potency is the dose needed for an effect; efficacy is the maximum achievable effect. A more potent drug is not necessarily more effective.

Therapeutic index: The gap between effective and toxic doses. Narrow-index drugs (warfarin, lithium, digoxin, phenytoin, aminoglycosides, levothyroxine) need level monitoring and careful attention to interactions.

Tolerance and tachyphylaxis: Diminishing response with repeated doses (nitrates, H2 blockers, opioids).

Half-Life and Dosing Math

Half-life (t½): Time for the plasma concentration to fall by 50%; it is proportional to volume of distribution divided by clearance.

Steady state is reached after about 4–5 half-lives of regular dosing, and about the same time is needed to eliminate most of a drug after stopping. For example, a drug with an 8-hour half-life reaches steady state in about 32–40 hours.

A loading dose reaches the target concentration faster (for example, magnesium sulfate or amiodarone).

First-order kinetics: A constant fraction is eliminated per unit time (most drugs). Zero-order kinetics: A constant amount is eliminated (phenytoin at high doses, alcohol), so small dose increases can cause large level jumps.

Long half-life drugs such as fluoxetine (norfluoxetine about 1–2 weeks) cause little discontinuation syndrome but take weeks to wash out; semaglutide's long half-life is why it is stopped 2 months before conception.

Pharmacogenetics

Gene Drugs Affected Clinical Consequence

CYP2D6 Codeine, tramadol, tamoxifen, many SSRIs and TCAs Ultrarapid metabolizers make excess morphine from codeine, which can cause respiratory depression in the patient or a breastfed infant ; the FDA (2017) contraindicates codeine and tramadol in children under 12 and warns against their use while breastfeeding. Poor metabolizers form less endoxifen from tamoxifen

CYP2C19 Clopidogrel, PPIs, citalopram and escitalopram, sertraline Poor metabolizers get less clopidogrel activation (higher stent thrombosis) and higher citalopram levels

CYP2C9 and VKORC1 Warfarin Variants predict lower dose needs and bleeding risk

HLA-B*15:02 Carbamazepine, oxcarbazepine, phenytoin Strongly predicts Stevens-Johnson syndrome/toxic epidermal necrolysis , especially in people of Asian ancestry; test before starting carbamazepine

HLA-B*58:01 Allopurinol Severe cutaneous reactions

TPMT and NUDT15 Azathioprine, mercaptopurine Deficiency causes life-threatening myelosuppression; test before starting

DPYD Fluorouracil, capecitabine Deficiency causes severe toxicity

G6PD deficiency (X-linked) Nitrofurantoin, sulfonamides, dapsone, primaquine, rasburicase Hemolysis ; also relevant to the newborn when nitrofurantoin is given near term

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines translate genotype results into dosing advice.

  • Drug Interactions Every WHNP Should Know
  • Interactions That Reduce Hormonal Contraception

Interacting Drug Effect US MEC Guidance

Rifampin, rifabutin Strong CYP3A4 induction lowers estrogen and progestin levels Combined pills, patch, ring, and POPs Category 3 ; implant Category 2 ; DMPA and IUDs Category 1

Enzyme-inducing antiseizure drugs (carbamazepine, oxcarbazepine, phenytoin, phenobarbital, primidone, topiramate >200 mg/day ) Lower hormone levels Combined methods and POPs Category 3 ; implant Category 2 ; DMPA and IUDs Category 1

St. John's wort CYP3A4 induction Breakthrough bleeding and pregnancy; advise a different method or avoid the herb

Some antiretrovirals (efavirenz; ritonavir-boosted regimens) Lower contraceptive levels, particularly with implants and pills Check current interaction resources; IUDs and DMPA are unaffected

Ulipristal acetate Progestins and ulipristal reduce each other's effect Wait at least 5 days after ulipristal before starting hormonal contraception

Tirzepatide Delayed gastric emptying lowers oral contraceptive exposure Non-oral method or barrier backup for 4 weeks after starting and each dose increase

  • Non-rifamycin antibiotics No reduction in effectiveness Category 1 ; no backup needed
  • Interactions Caused by Hormonal Contraception

Lamotrigine: Estrogen induces glucuronidation and cuts lamotrigine levels about 50% , which can cause seizures; levels rebound during the hormone-free week, which can cause toxicity. US MEC rates combined methods Category 3 with lamotrigine monotherapy; progestin-only methods and IUDs avoid the interaction.

Drospirenone plus potassium-raising drugs (ACE inhibitors, ARBs, spironolactone, potassium supplements, daily NSAIDs): Check potassium.

Levothyroxine: Estrogen raises thyroxine-binding globulin, so women may need a higher dose after starting oral estrogen.

Other High-Yield Interactions

  • Combination Risk
  • Warfarin with TMP-SMX, metronidazole, fluconazole, or fluoroquinolones INR rises, causing bleeding

SSRIs or SNRIs with tramadol, linezolid, triptans, St. John's wort, or MAOIs Serotonin syndrome (agitation, hyperthermia, clonus)

QT-prolonging drugs (ondansetron, azithromycin, fluoroquinolones, citalopram, methadone, antipsychotics) Torsades de pointes, especially with low potassium or magnesium

  • Clarithromycin or strong azoles with simvastatin or lovastatin Rhabdomyolysis
  • Methotrexate with TMP-SMX or NSAIDs Bone marrow and renal toxicity
  • PDE5 inhibitors with nitrates Severe hypotension
  • Paroxetine or fluoxetine with tamoxifen Less endoxifen, which may reduce efficacy
  • Calcium, iron, PPIs, or soy with levothyroxine Reduced absorption; separate by 4 hours
  • Grapefruit juice with CYP3A4 substrates (some statins and calcium channel blockers) Higher drug levels
  • Patient Education and Safe Prescribing

Reconcile medications at every visit, including OTC drugs, herbs, and supplements.

Use teach-back to confirm understanding of dosing, side effects, and warning signs.

Check interactions with a reliable database before adding any drug, especially for patients on anticoagulants, antiseizure drugs, antiretrovirals, or transplant medications.

Counsel on reproductive implications (teratogenicity, contraception needs, and lactation compatibility) whenever prescribing to a person who could become pregnant.